The Highly Efficient Suzuki-Miyaura Cross-Coupling of (Hetero)aryl Chlorides and (Hetero)arylboronic Acids Catalyzed by “Bulky-yet-Flexible” Palladium-PEPPSI Complexes in Air
作者:Jia-Sheng Ouyang、Yan-Fang Li、Fei-Dong Huang、Dong-Dong Lu、Feng-Shou Liu
DOI:10.1002/cctc.201701076
日期:2018.1.23
Pd–PEPPSI complexes were designed and synthesized. The relationship between catalyst structure and properties was systematically investigated. It was revealed that “bulky‐yet‐flexible” C3 bearing ancenaphthyl backbone was a highlyefficient precatalyst and could be successfully employed in Suzuki–Miyaura reactions of (hetero)arylchlorides with (hetero)arylboronic acids at a low palladium loading in the presence
[EN] SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS SUBSTITUÉS DE L'ACIDE 3-HÉTÉROAROYLAMINO-PROPIONIQUE ET LEUR UTILISATION COMME COMPOSÉS PHARMACEUTIQUES
申请人:SANOFI SA
公开号:WO2012101197A1
公开(公告)日:2012-08-02
The present invention relates to compounds of the formula (I), wherein A, D, E, L, G, R10, R30, R40, R50 and R60 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
申请人:RUF Sven
公开号:US20120252809A1
公开(公告)日:2012-10-04
The present invention relates to compounds of the formula I,
wherein A, D, E, L, G, R
10
, R
30
, R
40
, R
50
and R
60
have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
The invention relates to HSP90 inhibiting compounds consisting of the formula:
wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.